143 related articles for article (PubMed ID: 7493303)
1. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha.
Chemello L; Cavalletto L; Noventa F; Bonetti P; Casarin C; Bernardinello E; Pontisso P; Donada C; Casarin P; Belussi F
J Viral Hepat; 1995; 2(2):91-6. PubMed ID: 7493303
[TBL] [Abstract][Full Text] [Related]
2. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
3. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
[TBL] [Abstract][Full Text] [Related]
4. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
[TBL] [Abstract][Full Text] [Related]
5. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
6. GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy.
Pawlotsky JM; Roudot-Thoraval F; Muerhoff AS; Pellerin M; Germanidis G; Desai SM; Bastie A; Darthuy F; Rémiré J; Zafrani ES; Soussy CJ; Mushahwar IK; Dhumeaux D
J Med Virol; 1998 Jan; 54(1):26-37. PubMed ID: 9443106
[TBL] [Abstract][Full Text] [Related]
7. Alpha interferon treatment in chronic hepatitis C.
Idéo G; Bellobuono A; Mondazzi L; Tempini S; Bellati G; Idéo GM; Silini E
Clin Exp Rheumatol; 1995; 13 Suppl 13():S167-73. PubMed ID: 8730501
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
[TBL] [Abstract][Full Text] [Related]
10. Alanine aminotransferase and HCV-RNA responses following interferon therapy of HCV-RNA positive chronic hepatitis.
Arase Y; Kumada H; Chayama K; Tsubota A; Ikeda K; Saitoh S; Sakai Y; Matsumoto T; Kobayashi M
Gastroenterol Jpn; 1992 Oct; 27(5):646-51. PubMed ID: 1330798
[TBL] [Abstract][Full Text] [Related]
11. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.
Orito E; Mizokami M; Nakano T; Terashima H; Nojiri O; Sakakibara K; Mizuno M; Ogino M; Nakamura M; Matsumoto Y
J Med Virol; 1994 Dec; 44(4):410-4. PubMed ID: 7897373
[TBL] [Abstract][Full Text] [Related]
12. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
13. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
14. Two years versus six months of interferon therapy for chronic hepatitis C.
Farrell GC
Dig Dis Sci; 1996 Dec; 41(12 Suppl):93S-98S. PubMed ID: 9011483
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.
Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):213-9. PubMed ID: 15908318
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
[TBL] [Abstract][Full Text] [Related]
20. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
